Jiewei Zeng

747 total citations · 1 hit paper
16 papers, 520 citations indexed

About

Jiewei Zeng is a scholar working on Oncology, Dermatology and Genetics. According to data from OpenAlex, Jiewei Zeng has authored 16 papers receiving a total of 520 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Dermatology and 3 papers in Genetics. Recurrent topics in Jiewei Zeng's work include Dermatology and Skin Diseases (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Allergic Rhinitis and Sensitization (3 papers). Jiewei Zeng is often cited by papers focused on Dermatology and Skin Diseases (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Allergic Rhinitis and Sensitization (3 papers). Jiewei Zeng collaborates with scholars based in United States, Canada and Japan. Jiewei Zeng's co-authors include Kenji Kabashima, Kristian Reich, Thomas Bieber, Jonathan I. Silverberg, Barry Ladizinski, Alvina D. Chu, Weily Soong, Marjolein de Bruin‐Weller, Xiaohong Huang and Thomas Werfel and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Science of The Total Environment.

In The Last Decade

Jiewei Zeng

15 papers receiving 511 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

2021 250 citations Kristian Reich, Henrique D. Teixeira et al. The Lancet profile →

Peers

Countries citing papers authored by Jiewei Zeng

Since Specialization

Citations

This map shows the geographic impact of Jiewei Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiewei Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiewei Zeng more than expected).

Fields of papers citing papers by Jiewei Zeng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiewei Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiewei Zeng. The network helps show where Jiewei Zeng may publish in the future.

Co-authorship network of co-authors of Jiewei Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Jiewei Zeng. A scholar is included among the top collaborators of Jiewei Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiewei Zeng. Jiewei Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study 2025 ·The Lancet Haematology ·Shaji Kumar, Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vânia Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, (unknown), Muhammad Jalaluddin, Jiewei Zeng, Jeremy A. Ross, (unknown), Philippe Moreau	0
2	Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma 2023 ·International Journal of Clinical Oncology ·Hideki Goto, Satoshi Ito, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara, Koji Kato, (unknown), Yasuhito Terui, Sumiko Okubo, (unknown), Jiewei Zeng, (unknown), Mohamed Badawi, Jeremy A. Ross, Koji Izutsu	3
3	P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Jonathan L. Kaufman, Hang Quach, Rachid Baz, Annette Juul Vangsted, Shir‐Jing Ho, Niels Abildgaard, Jacob P. Laubach, Vincent Ribrag, Simon Gibbs, Eva Medvedova, Peter W. Voorhees, Muhammad Jalaluddin, Jiewei Zeng, Jeremy A. Ross, Xifeng Wang, (unknown), Orlando F. Bueno, Yan Luo, Nizar J. Bahlis	1
4	Network evolution and risk assessment of the global phosphorus trade 2022 ·The Science of The Total Environment ·Bing Li, (unknown), Jing‐Cheng Han, (unknown), Jiewei Zeng, (unknown), Yang Zhou, (unknown), Xiaofeng Wu, Yuefei Huang	25
5	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results 2021 ·Journal of Allergy and Clinical Immunology ·Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Antonio Costanzo, David Rosmarin, Charles Lynde, John Liu, (unknown), Jiewei Zeng, Barry Ladizinski, Alvina D. Chu, Kristian Reich	76
6	Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial 2021 ·Dermatology and Therapy ·Kim Papp, (unknown), Jiewei Zeng, Mary Flack, (unknown), Stephen K. Tyring	8
7	Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial breakdown → 2021 ·The Lancet ·Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Thomas Werfel, Jiewei Zeng, Xiaohong Huang, Xiaofei Hu, Barbara A. Hendrickson, Barry Ladizinski, Alvina D. Chu, Jonathan I. Silverberg	250
8	25511 Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2) 2021 ·Journal of the American Academy of Dermatology ·Eric L. Simpson, Marjolein de Bruin‐Weller, Vimal H. Prajapati, Brian Calimlim, Henrique D. Teixeira, Jiewei Zeng, (unknown), Jonathan I. Silverberg	1
9	14027 Long-term efficacy and safety of continuous q12w risankizumab: Results from the open-label extension LIMMitless trial 2020 ·Journal of the American Academy of Dermatology ·Kim Papp, Mark Lebwohl, Jiewei Zeng, Simone Rubant, Joaquin Valdes, (unknown)	1
10	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Pivotal Phase 3, Randomised, Double-Blind, Placebo-Controlled Study (AD Up) 2020 ·SSRN Electronic Journal ·Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Thomas Werfel, Jiewei Zeng, Xiaohong Huang, (unknown), Barbara A. Hendrickson, Barry Ladizinski, Alvina D. Chu, Jonathan I. Silverberg	1
11	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours 2018 ·British Journal of Cancer ·Jordan Berlin, Ramesh K. Ramanathan, John H. Strickler, Deepa S. Subramaniam, John L. Marshall, Yoon‐Koo Kang, (unknown), Matthew W. Dudley, Jiewei Zeng, Caroline Nickner, Hao Xiong, Philip Komarnitsky, Stacie Peacock Shepherd, Herbert I. Hurwitz, Heinz‐Josef Lenz	27
12	Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus 2018 ·Clinical Pharmacokinetics ·Mukul Minocha, Jiewei Zeng, Jan Paul Medema, Mohamed I. A. Othman	10
13	Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials 2018 ·Clinical Pharmacology in Drug Development ·Mohamed‐Eslam F. Mohamed, Jiewei Zeng, Patrick Marroum, In‐Ho Song, Mohamed I. A. Othman	47
14	Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor 2018 ·Cancer ·Glenwood Goss, Everett E. Vokes, Michael S. Gordon, Leena Gandhi, Kyriakos P. Papadopoulos, Drew Rasco, (unknown), Katharine L. Chu, (unknown), Rajendar K. Mittapalli, Ho‐Jin Lee, Jiewei Zeng, Lisa Roberts-Rapp, (unknown), Peter Ansell, Edward B. Reilly, Christopher Ocampo, Kyle D. Holen, Anthony W. Tolcher	52
15	Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity 2017 ·Clinical Pharmacology & Therapeutics ·Mohamed‐Eslam F. Mohamed, Jiewei Zeng, Ping Jiang, Balakrishna Hosmane, Mohamed I. A. Othman	15
16	ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). 2015 ·Journal of Clinical Oncology ·Glenwood Goss, Everett E. Vokes, Michael S. Gordon, Leena Gandhi, Kyriakos P. Papadopoulos, Drew Rasco, (unknown), (unknown), Katharine L. Chu, (unknown), Hao Xiong, Ho‐Jin Lee, Jiewei Zeng, Lisa Roberts-Rapp, Peter Ansell, (unknown), Kyle D. Holen, Anthony W. Tolcher	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact